Literature DB >> 32632094

Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia.

Manuel Abecasis1, Nicholas C P Cross2, Manuel Brito3, Isabelina Ferreira1, Kathleen M Sakamoto4, Nobuko Hijiya5, Joannah Score2, Robert Peter Gale6.   

Abstract

Our concept of cancer latency, the interval from when a cancer starts until it is diagnosed, has changed dramatically. A prior widely-used definition was the interval between an exposure to a cancer-causing substance and cancer diagnosis. However, this definition does not accurately reflect current knowledge of how most cancers develop assuming, mostly incorrectly, one exposure is the sole cause of a cancer, ignoring the possibility the cancer being considered would have developed anyway but that the exposure accelerated cancer development and eliding the randomness in when a cancer is diagnosed. We show, using chronic myeloid leukaemia as a model, that defining cancer latency is not as simple as it once seemed. It is difficult or impossible to know at which event or mutation to start to clock to measure cancer latency. It is equally difficult to know when to stop the clock given the stochastic nature of when cancers are diagnosed. Importantly, even in genetically-identical twins with the same driver mutation intervals to develop cancer vary substantially. And we discuss other confonders. Clearly we need a new definition of cancer latency or we need to abandon the concept of cancer latency in the modern era of cancer biology.

Entities:  

Mesh:

Year:  2020        PMID: 32632094     DOI: 10.1038/s41375-020-0957-z

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  30 in total

Review 1.  The molecular biology of chronic myeloid leukemia.

Authors:  M W Deininger; J M Goldman; J V Melo
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

Review 2.  Chronic myeloid leukemia--advances in biology and new approaches to treatment.

Authors:  John M Goldman; Junia V Melo
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

3.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

4.  A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns.

Authors:  Faiyaz Notta; Michelle Chan-Seng-Yue; Mathieu Lemire; Yilong Li; Gavin W Wilson; Ashton A Connor; Robert E Denroche; Sheng-Ben Liang; Andrew M K Brown; Jaeseung C Kim; Tao Wang; Jared T Simpson; Timothy Beck; Ayelet Borgida; Nicholas Buchner; Dianne Chadwick; Sara Hafezi-Bakhtiari; John E Dick; Lawrence Heisler; Michael A Hollingsworth; Emin Ibrahimov; Gun Ho Jang; Jeremy Johns; Lars G T Jorgensen; Calvin Law; Olga Ludkovski; Ilinca Lungu; Karen Ng; Danielle Pasternack; Gloria M Petersen; Liran I Shlush; Lee Timms; Ming-Sound Tsao; Julie M Wilson; Christina K Yung; George Zogopoulos; John M S Bartlett; Ludmil B Alexandrov; Francisco X Real; Sean P Cleary; Michael H Roehrl; John D McPherson; Lincoln D Stein; Thomas J Hudson; Peter J Campbell; Steven Gallinger
Journal:  Nature       Date:  2016-10-12       Impact factor: 49.962

5.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

Review 6.  CHIP, ICUS, CCUS and other four-letter words.

Authors:  R Bejar
Journal:  Leukemia       Date:  2017-06-08       Impact factor: 11.528

Review 7.  Chronic myeloid leukaemia.

Authors:  Jane F Apperley
Journal:  Lancet       Date:  2014-12-05       Impact factor: 79.321

8.  Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.

Authors:  C Biernaux; M Loos; A Sels; G Huez; P Stryckmans
Journal:  Blood       Date:  1995-10-15       Impact factor: 22.113

9.  The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.

Authors:  S Bose; M Deininger; J Gora-Tybor; J M Goldman; J V Melo
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

Review 10.  Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor.

Authors:  Sachiko Ezoe
Journal:  Int J Environ Res Public Health       Date:  2012-07-10       Impact factor: 3.390

View more
  2 in total

Review 1.  Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.

Authors:  Michele Baccarani; Robert Peter Gale
Journal:  Leukemia       Date:  2021-05-17       Impact factor: 11.528

Review 2.  CD44 and Tumor-Derived Extracellular Vesicles (TEVs). Possible Gateway to Cancer Metastasis.

Authors:  Rafał Szatanek; Monika Baj-Krzyworzeka
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.